Results 141 to 150 of about 104,745 (290)
BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects [PDF]
, 2020 Paraskevi Apostolou, Florentia Fostira, Charalambos Kouroussis, Despoina Kalfakakou, Angeliki Delimitsou, Sofia Agelaki, Nikolaos Androulakis, Christos Christodoulou, K. Kalbakis, A. Kalykaki, Elias Sanidas, Christos Papadimitriou, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis, Drakoulis Yannoukakos, Irene Konstantopoulou, Emmanouil Saloustros +17 moreopenalex +1 more sourceOlaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol
International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.What's new?
PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul +15 morewiley +1 more sourceDelivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience
International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.What's new?
CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter +31 morewiley +1 more sourceAssociation Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer
International Journal of General MedicineYu Luo,1,2 Ru Pan,1,2 Hui Rao,2,3 Xing Chen,4 Haikun Yang1,2 1Department of Gynaecology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Meizhou Municipal Engineering and Technology Research Center ...Luo Y, Pan R, Rao H, Chen X, Yang Hdoaj The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. [PDF]
, 2019 Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk.Aalfs, Cora M, ABCTB Investigators, Adank, Muriel A, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A, Ahearn, Thomas, Aittomäki, Kristiina, Ambrosone, Christine B, Andrews, Lesley, Anton-Culver, Hoda, Antonenkova, Natalia N, Arndt, Volker, Arnold, Norbert, Aronson, Kristan J, Arun, Banu K, Asseryanis, Ella, Auber, Bernd, Auvinen, Päivi, Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B, Barnes, Daniel R, Barrowdale, Daniel, Barwell, Julian, Beane Freeman, Laura E, Beauparlant, Charles Joly, Beckmann, Matthias W, Behrens, Sabine, Benitez, Javier, Berger, Raanan, Bermisheva, Marina, Blanco, Amie M, Blomqvist, Carl, Bogdanova, Natalia V, Bogliolo, Massimo, Bojesen, Anders, Bojesen, Stig E, Bolla, Manjeet K, Bonanni, Bernardo, Borg, Ake, Brady, Angela F, Brauch, Hiltrud, Brenner, Hermann, Brüning, Thomas, Burwinkel, Barbara, Buys, Saundra S, Cadoo, Karen, Caldés, Trinidad, Caleca, Laura, Caliebe, Almuth, Caligo, Maria A, Campa, Daniele, Campbell, Ian G, Canzian, Federico, Castelao, Jose E, Catucci, Irene, Chang-Claude, Jenny, Chanock, Stephen J, Claes, Kathleen BM, Clarke, Christine L, Collavoli, Anita, Conner, Thomas A, Cox, David G, Cybulski, Cezary, Czene, Kamila, Daly, Mary B, de la Hoya, Miguel, Dennis, Joe, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Dite, Gillian S, Ditsch, Nina, Domchek, Susan M, Dorfling, Cecilia M, Dos-Santos-Silva, Isabel, Durda, Katarzyna, Dwek, Miriam, Eccles, Diana M, Ekici, Arif B, Eliassen, A Heather, Ellberg, Carolina, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Figlioli, Gisella, Figueroa, Jonine, Flyger, Henrik, Foulkes, William D, Friebel, Tara M, Friedman, Eitan, Gabrielson, Marike, Gaddam, Pragna, Kiiski, Johanna I, Lasheras, Sandra Viz, Leslie, Goska, Michailidou, Kyriaki, Muranen, Taru A, Pujol, Roser +99 morecore Welcome Pathogens: Transient Heat Dampens Immune Responses to Acibenzolar‐S‐Methyl in Apple Plants
Plant, Cell &Environment, Volume 49, Issue 3, Page 1229-1248, March 2026.ABSTRACT
Climate change affects plant‐pathogen interactions, with disease outcome varying depending on the pathosystem and environmental scenario. In Arabidopsis, a thermo‐sensitive module of salicylic acid (SA) signalling makes immunity vulnerable to heat.Erwan Chavonet, Bao‐huynh Nguyen, Christelle Heintz, Raphaël Cournol, Jitka Široká, Ondřej Novák, Romain Larbat, Matthieu Gaucher, Marie‐Noëlle Brisset, Florent Pantin, Alexandre Degrave +10 morewiley +1 more sourceExperiences of metastatic prostate cancer patients with a mainstream genetic testing pathway
International Journal of Cancer, Volume 158, Issue 4, Page 984-993, 15 February 2026.What's new?
Germline genetic testing can direct cancer patients towards more optimal treatment options and relatives towards targeted cancer screening or preventive measures. In the case of prostate cancer, many patients are eligible for such testing, though little is known about its psychosocial impacts.Michiel Vlaming, Eveline M. A. Bleiker, Gina Schijven, Lambertus A. L. M. Kiemeney, Harm H. E. van Melick, Jarmo C. B. Hunting, M. Arjen Noordzij, Aart Beeker, Diederik M. Somford, Henk G. van der Poel, Carl J. Wijburg, Bart P. Wijsman, Robert J. Hoekstra, R. Jeroen A. van Moorselaar, Bart P. J. van Bezooijen, Richard P. Meijer, Martijn B. Busstra, H. Pieter van den Berg, Debbie G. J. Robbrecht, Benjamin H. J. Doornweerd, Inge M. van Oort, Margreet G. E. M. Ausems +21 morewiley +1 more sourceRISK FACTORS OF OVARIAN CANCER AND POSSIBLE PREVENTIVE STRATEGIES
Фундаментальная и клиническая медицина, 2018 Here we review the current data on prevention, diagnosis, and treatment of ovarian cancer, one of the most prevalent genitourinary cancers characterized by high mortality and case fatality rates due to the lack of efficient screening and treatment ...OLGA B. Karelina, NATALIA V. Artymuk, TATIANA I. Fetisova +2 moredoaj Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer
FEBS Open Bio, Volume 16, Issue 2, Page 432-446, February 2026.CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi +3 morewiley +1 more source
